Although CP shows early bactericidal activity in human tuberculosis and has been prescribed as part of a treatment for multidrug-resistant tuberculosis, the latest in vivo studies point to better efficacy of MXF [8,9]. The gene discussed is CP; the disease is tuberculosis.